The rumored $400 billion merger discussions between AstraZeneca and Bristol Myers Squibb didn’t get very far, but the episode offered another indication of the strategic pressure facing large pharmaceutical companies as they confront patent expirations and an increasingly demanding commercial environment. The question for pharma leaders is no longer simply…
In Part 1 of this series, we discussed Integrated Evidence Plans (IEPs) whose purpose is to identify and prioritize evidence gaps aligned with commercial goals to obtain regulatory approval in markets of interest, optimize access, and achieve a price that reflects the holistic value of a given asset. We noted…
Traditionally, launch sequencing has been guided by market size, eligible patient population, and the likelihood of securing market access and adoption. While these criteria are still important, they’re no longer sufficient. Growing budget constraints, more stringent evidence requirements, and the rise of external reference pricing and transparency are forcing pharma…
In a previous column, I discussed how pharmaceutical and medical device companies are adapting their commercial model approaches in critical areas to address growing economic, market and other competitive pressures. This adaptation is underscored in our new Numerof & Associates 2023 Commercial Model Report, which reveals the strategic changes that…
For years, lawmakers have targeted the pharmaceutical industry, blaming it for the high cost of healthcare – its role in the management of Covid-19 notwithstanding. Despite recent breakthroughs to rid the world of its worst scourges, both the U.S. and EU appear to regard pharma as the single worst actor…
With spiraling cost inflation and outcomes that lag many other developed economies, the US government’s healthcare insurance authority (CMS), is driving reform aimed at better quality and lower cost, and private payers are following suit. Both state and private payers are moving toward alternative payment models, like value-based payments, that…
